The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine
whether reducing subclinical inflammation lessens insulin resistance in healthy, obese
volunteers. The study findings may lead to new strategies for preventing type 2 diabetes. In
diabetes, blood sugar is higher than normal and can result in serious medical problems, such
as blindness and kidney failure. People with subclinical inflammation-inflammation that does
not produce symptoms, such as fever, pain, or skin redness-are at increased risk for
diabetes. Although the reasons for this are not completely understood, it is known that
subclinical inflammation exacerbates insulin resistance, which is a cause of diabetes.
Insulin is a hormone that helps control blood sugar, and when it does not work properly, the
condition is known as insulin resistance.
Normal, healthy volunteers between 18 and 45 years old with a body mass index of at least 30
kg/m2 and who have subclinical inflammation (determined by blood tests) may be eligible for
this study. Candidates must be non-smokers and must not have an alcohol or drug problem.
Candidates will be screened with a medical history and physical examination,
electrocardiogram, and blood and urine tests. Participants will maintain a standard diet and
undergo tests and procedures during a 14-day inpatient stay at the Phoenix Indian Medical
Center.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)